Y. Nisizaki

发表

Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study)

H. Kakeya, K. Tsushima, N. Uemura, 2022, medRxiv.